menu search

HAE / Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director, Investor Relations and Treasury Chris Simon – Chief Executive Officer Stewart Strong – President of our Global Hospital business James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Group Lee Jagoda – CJS Securities Andrew Cooper – Raymond James Mike Matson – Needham & Company Michael Petusky – Barrington Research Operator Good day and thank you for standing by, and welcome to the Second Quarter 2024 Haemonetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. Read More
Posted: Nov 3 2023, 18:21
Author Name: Seeking Alpha
Views: 100960

HAE News  

Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

By Seeking Alpha
November 3, 2023

Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

Haemonetics Corporation (NYSE:HAE ) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director more_horizontal

Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up

By Zacks Investment Research
November 3, 2023

Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up

The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) more_horizontal

Haemonetics (HAE) is an Incredible Growth Stock: 3 Reasons Why

By Zacks Investment Research
October 20, 2023

Haemonetics (HAE) is an Incredible Growth Stock: 3 Reasons Why

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes. more_horizontal

Haemonetics (HAE) Moves to Strong Buy: Rationale Behind the Upgrade

By Zacks Investment Research
October 11, 2023

Haemonetics (HAE) Moves to Strong Buy: Rationale Behind the Upgrade

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy more_horizontal

Haemonetics (HAE) Announces Agreement to Acquire OpSens

By Zacks Investment Research
October 11, 2023

Haemonetics (HAE) Announces Agreement to Acquire OpSens

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market. more_horizontal

Opsens stock soars on takeover deal with Haemonetics

By Proactive Investors
October 10, 2023

Opsens stock soars on takeover deal with Haemonetics

Opsens Inc shares surged 47% to $2.84 in midday trading on Tuesday after the cardiology-focused medical device company agreed to be acquired by glob more_horizontal

Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?

By Zacks Investment Research
October 4, 2023

Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?

Here is how Haemonetics (HAE) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year. more_horizontal

HAE vs. SYK: Which Stock Is the Better Value Option?

By Zacks Investment Research
September 25, 2023

HAE vs. SYK: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two stock more_horizontal


Search within

Pages Search Results: